2026 Trends in Drug Benefit Design Report
PSG announces the results of its extensive research on the latest trends in drug benefit design. Plan sponsors face complex decisions and challenges…
Read Post
Insights
Categories
Topics
Categories
Topics
Oncologists May Prescribe New Neutropenia Agent Over Others in Class, but Therapy Faces Another Challenge
Republished with Permission from AIS Health The FDA recently approved the first novel long-acting granulocyte colony-stimulating factor (G-CSF) in more…
Read Post
A Closer Look at the Complexities of PBM Satisfaction
Choosing, negotiating a contract, and navigating a relationship with a pharmacy benefit manager (PBM) isn’t one size fits all. No single PBM is “best”…
Read Post
PSG Announces Results of Highly Comprehensive Pharmacy Benefit Manager Survey
Customer Satisfaction Report Dives into Current PBM Sentiment by Plan Sponsors DALLAS, TX – Pharmaceutical Strategies Group (PSG), an EPIC company, has released its…
Read Post
The Inflation Reduction Act: Power Ranking the Top Impacts for Medicare Health Plans and PBMs
Much has been written about the sweeping changes contained in the Inflation Reduction Act of 2022 (IRA), including provisions that affect drug pricing. I’ve…
Read Post
2023 Formulary Changes: OptumRx
Get the Full Analysis of the Big 3 Formulary Changes: Summary of the Big 3 PBM 2023 Formulary Changes 2023 Formulary Changes: CVS Health…
Read Post
2023 Formulary Changes: CVS Health
Get the Full Analysis of the Big 3 Formulary Changes: Summary of the Big 3 PBM 2023 Formulary Changes 2023 Formulary…
Read Post
2023 Formulary Changes: Express Scripts
Get the Full Analysis of the Big 3 Formulary Changes: Summary of the Big 3 PBM 2023 Formulary Changes 2023 Formulary Changes: CVS Health…
Read Post
Summary of the Big 3 PBM 2023 Formulary Changes
Get the Full Analysis of the Big 3 Formulary Changes: 2023 Formulary Changes: CVS Health 2023 Formulary Changes: Express Scripts 2023 Formulary Changes: OptumRx…
Read Post
No Pain, No ‘Graine: Strategies for Optimized Use of New Migraine Therapies
Migraines represent the world’s third most prevalent illness. A new class of drugs called calcitonin gene-related peptide (CGRP) inhibitors entered the market in 2018.
Read Post
Biosimilars Are Picking Up Market Share, but Some Uncertainties Still Exist
Republished with Permission from AIS Health Since the FDA’s approval of the first biosimilar — Zarxio (filgrastim-sndz) from Sandoz, a…
Read Post
Specialty Trend Rose in 2021, but Biosimilars Are Having Impact
By Angela Maas Republished with Permission from AIS Health Specialty drug trend in 2021 largely recovered from the hit…
Read Post